{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:12:16Z","timestamp":1790781136951,"version":"4.1.0"},"reference-count":178,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00865","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T05:23:29Z","timestamp":1591161809000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":74,"title":["Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide"],"prefix":"10.3389","volume":"11","author":[{"given":"Alessandra","family":"Soriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Hern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/annrheumdis-2014-206580","article-title":"Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers","volume":"74","author":"Federici","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol Cell"},{"key":"B3","first-page":"274","article-title":"Familial mediterranean fever: genetic update","volume":"16","author":"Soriano","year":"2014","journal-title":"Isr Med Assoc J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrrheum.2013.174","article-title":"A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin","volume":"10","author":"Ozen","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3389\/fimmu.2017.00399","article-title":"NF-kB pathway in autoinflammatory diseases: dysregulation of protein modifications by ubiquitin defines a new category of autoinflammatory diseases","volume":"8","author":"Aksentijevich","year":"2017","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/BOR.0000000000000207","article-title":"Newly recognized mendelian disorders with rheumatic manifestations","volume":"27","author":"de Jesus","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev-med-050715-104506","article-title":"The type i interferonopathies","volume":"68","author":"Lee-Kirsch","year":"2017","journal-title":"Annu Rev Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2010.177","article-title":"Non-canonical NF-kappaB signaling pathway","volume":"21","author":"Sun","year":"2011","journal-title":"Cell Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/ni.3777","article-title":"The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation","volume":"18","author":"Manthiram","year":"2017","journal-title":"Nat Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s11739-016-1466-y","article-title":"Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens","volume":"11","author":"Cattalini","year":"2016","journal-title":"Intern Emerg Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1136\/ard.2004.023697","article-title":"EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees","volume":"63","author":"Dougados","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","article-title":"EULAR recommendations for the management of familial mediterranean fever","volume":"75","author":"Ozen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/annrheumdis-2015-207546","article-title":"Recommendations for the management of autoinflammatory diseases","volume":"74","author":"Ter Haar","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1136\/annrheumdis-2011-201268","article-title":"Treatment of autoinflammatory diseases: results from the eurofever registry and a literature review","volume":"72","author":"Ter Haar","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/archderm.118.7.453","article-title":"Colchicine. new uses of an old, old drug","volume":"118","author":"Malkinson","year":"1982","journal-title":"Arch Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(97)09408-7","article-title":"Familial mediterranean fever","volume":"351","author":"Ben-Chetrit","year":"1998","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S0049-0172(98)80028-0","article-title":"Colchicine: 1998 update","volume":"28","author":"Ben-Chetrit","year":"1998","journal-title":"Semin Arthritis Rheum"},{"key":"B19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ejim.2010.09.010","article-title":"Colchicine in clinical medicine. a guide for internists","volume":"21","author":"Cocco","year":"2010","journal-title":"Eur J Intern Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1056\/NEJM197212212872514","article-title":"Colchicine for familial mediterranean fever","volume":"287","author":"Goldfinger","year":"1972","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJM197410312911804","article-title":"Colchicine therapy for familial mediterranean fever. a double-blind trial","volume":"291","author":"Dinarello","year":"1974","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJM197410312911803","article-title":"A controlled trial of colchicine in preventing attacks of familial mediterranean fever","volume":"291","author":"Zemer","year":"1974","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM198604173141601","article-title":"Colchicine in the prevention and treatment of the amyloidosis of familial mediterranean fever","volume":"314","author":"Zemer","year":"1986","journal-title":"N Engl J Med"},{"key":"B24","unstructured":"Information for Healthcare Professionals: New Safety Information for Colchicine (marketed as Colcrys)2009"},{"key":"B25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/hep.1840110208","article-title":"Effect of colchicine on lymphocyte and monocyte function and its relation to fibroblast proliferation in primary biliary cirrhosis","volume":"11","author":"Kershenobich","year":"1990","journal-title":"Hepatology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"13560","DOI":"10.1021\/bi00212a023","article-title":"Molecular mechanism of colchicine action: induced local unfolding of beta-tubulin","volume":"32","author":"Sackett","year":"1993","journal-title":"Biochemistry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1042\/bj3230189","article-title":"Response of microtubules to the addition of colchicine and tubulin-colchicine: evaluation of models for the interaction of drugs with microtubules","volume":"323","author":"Vandecandelaere","year":"1997","journal-title":"Biochem J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1021\/bi00532a019","article-title":"Interaction of tubulin with single ring analogues of colchicine","volume":"21","author":"Andreu","year":"1982","journal-title":"Biochemistry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/blood.V83.9.2451.bloodjournal8392451","article-title":"P-glycoprotein expression and function in circulating blood cells from normal volunteers","volume":"83","author":"Klimecki","year":"1994","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0306-9877(98)90031-7","article-title":"Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial mediterranean fever and other inflammatory diseases?","volume":"51","author":"Ben-Chetrit","year":"1998","journal-title":"Med Hypotheses"},{"key":"B31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1084\/jem.171.3.715","article-title":"Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents","volume":"171","author":"Ding","year":"1990","journal-title":"J Exp Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1172\/JCI118147","article-title":"Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils","volume":"96","author":"Cronstein","year":"1995","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/j.1476-5381.1996.tb15353.x","article-title":"Involvement of secretory phospholipase A2 activity in the zymosan rat air pouch model of inflammation","volume":"117","author":"Paya","year":"1996","journal-title":"Br J Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.V98.3.851","article-title":"The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments","volume":"98","author":"Mansfield","year":"2001","journal-title":"Blood"},{"key":"B35","first-page":"7","article-title":"Effect of colchicine and cytokines on MEFV expression and C5a inhibitor activity in human primary fibroblast cultures","volume":"4","author":"Abedat","year":"2002","journal-title":"Isr Med Assoc J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/rheumatology\/kei140","article-title":"Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis","volume":"45","author":"Ben-Chetrit","year":"2006","journal-title":"Rheumatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/BF00194404","article-title":"Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects","volume":"46","author":"Rochdi","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jbspin.2006.03.006","article-title":"Colchicine today","volume":"73","author":"Niel","year":"2006","journal-title":"Joint Bone Spine"},{"key":"B40","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.semarthrit.2013.04.011","article-title":"Evidence-based recommendations for the practical management of familial mediterranean Fever","volume":"43","author":"Hentgen","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"B41","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s10067-003-0739-9","article-title":"Colchicine treatment in children with familial Mediterranean fever","volume":"22","author":"Ozkaya","year":"2003","journal-title":"Clin Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.autrev.2012.07.019","article-title":"Familial mediterranean fever: new phenotypes","volume":"12","author":"Soriano","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semarthrit.2017.03.006","article-title":"Colchicine resistance and intolerance in familial mediterranean fever: definition, causes, and alternative treatments","volume":"47","author":"Ozen","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"B44","first-page":"2620","article-title":"Intravenous colchicine for treatment of patients with familial mediterranean fever unresponsive to oral colchicine","volume":"30","author":"Lidar","year":"2003","journal-title":"J Rheumatol"},{"key":"B45","first-page":"S105","article-title":"Intravenous colchicine treatment for six months: adjunctive therapy in familial mediterranean fever (FMF) unresponsive to oral colchicine","volume":"27","author":"Rozenbaum","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"B46","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1936960","article-title":"Role of colchicine treatment in tumor necrosis factor receptor associated periodic syndrome (TRAPS): real life data from the AIDA Network","author":"Vitale","year":"2020","journal-title":"Mediators Inflamm"},{"key":"B47","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.semarthrit.2010.06.009","article-title":"The familial mediterranean fever gene as a modifier of periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome","volume":"40","author":"Berkun","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"B48","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.semarthrit.2015.07.005","article-title":"Colchicine as a therapeutic option in periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome","volume":"45","author":"Butbul Aviel","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"B49","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jbspin.2015.08.017","article-title":"Is colchicine an effective treatment in periodic fever, aphtous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome?","volume":"83","author":"Dusser","year":"2016","journal-title":"Joint Bone Spine"},{"key":"B50","first-page":"S114","article-title":"Protracted febrile myalgia in children and young adults with familial mediterranean fever: analysis of 15 patients and suggested criteria for working diagnosis","volume":"25","author":"Kaplan","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"939847","DOI":"10.1155\/2013\/939847","article-title":"Biological treatments: new weapons in the management of monogenic autoinflammatory disorders","volume":"2013","author":"Vitale","year":"2013","journal-title":"Mediators Inflamm"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids\u2013new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jbspin.2007.10.004","article-title":"Early suppression of familial Mediterranean fever attacks by single medium dose methyl-prednisolone infusion","volume":"75","author":"Erken","year":"2008","journal-title":"Joint Bone Spine"},{"key":"B54","first-page":"1708","article-title":"Protracted febrile myalgia in patients with familial mediterranean fever","volume":"21","author":"Langevitz","year":"1994","journal-title":"J Rheumatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.semarthrit.2017.10.008","article-title":"Protracted febrile myalgia syndrome treated with pulse of corticosteroids","volume":"47","author":"Rom","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"B56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.autrev.2015.08.008","article-title":"Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center","volume":"15","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B57","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fimmu.2017.00299","article-title":"Disease phenotype and outcome depending on the age at disease onset in patients carrying the R92Q low-penetrance variant in TNFRSF1A gene","volume":"8","author":"Ruiz-Ortiz","year":"2017","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"A188","DOI":"10.1186\/1546-0096-11-S1-A188","article-title":"Treatment responses in TRAPS: Eurofever\/ Eurotraps","volume":"11","author":"Lachmann","year":"2013","journal-title":"Pediatr Rheumatol Online J"},{"key":"B59","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11926-017-0670-8","article-title":"Autoinflammatory Diseases with Periodic Fevers","volume":"19","author":"Sag","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"B60","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1651-2227.2009.01554.x","article-title":"A clinical review of 105 patients with PFAPA (a periodic fever syndrome)","volume":"99","author":"Feder","year":"2010","journal-title":"Acta Paediatr"},{"key":"B61","first-page":"269","article-title":"Diagnosis of PFAPA syndrome applied to a cohort of 17 adults with unexplained recurrent fevers","volume":"30","author":"Cantarini","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10067-016-3317-7","article-title":"A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome","volume":"36","author":"Rigante","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.medcle.2017.11.043","article-title":"Monogenic autoinflammatory diseases: General concepts and presentation in adult patients","volume":"150","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2018","journal-title":"Med Clin"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.ijporl.2012.07.020","article-title":"Comparison of conventional and low dose steroid in the treatment of PFAPA syndrome: preliminary study","volume":"76","author":"Yazgan","year":"2012","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"CD008669","DOI":"10.1002\/14651858.CD008669.pub3","article-title":"Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA)","volume":"12","author":"Burton","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B66","first-page":"S99","article-title":"Treatment options in colchicine resistant familial mediterranean fever patients: thalidomide and etanercept as adjunctive agents","volume":"24","author":"Seyahi","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"B67","first-page":"1221","article-title":"Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial","volume":"298","author":"Drenth","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"B68","first-page":"23","article-title":"Dapsone as an alternative therapy in children with familial mediterranean fever","volume":"22","author":"Salehzadeh","year":"2012","journal-title":"Iran J Pediatr"},{"key":"B69","first-page":"S41","article-title":"The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicine-resistant familial Mediterranean fever patients","volume":"22","author":"Calguneri","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/rheumatology\/35.11.1188","article-title":"Resolving familial Mediterranean fever attacks with interferon alpha","volume":"35","author":"Tankurt","year":"1996","journal-title":"Br J Rheumatol"},{"key":"B71","first-page":"1362","article-title":"Interferon-alpha as a treatment modality for colchicine- resistant familial Mediterranean fever","volume":"35","author":"Tweezer-Zaks","year":"2008","journal-title":"J Rheumatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5414\/CN106447","article-title":"Successful treatment of renal AA amyloidosis in familial mediterranean fever with pegylated alpha-2a interferon","volume":"75","author":"Vandecasteele","year":"2011","journal-title":"Clin Nephrol"},{"key":"B73","first-page":"S37","article-title":"The effect of interferon alpha administration on acute attacks of familial mediterranean fever: a double-blind, placebo-controlled trial","volume":"22","author":"Tunca","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"B75","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1084\/jem.159.1.126","article-title":"Identification of a specific interleukin 1 inhibitor in the urine of febrile patients","volume":"159","author":"Liao","year":"1984","journal-title":"J Exp Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1172\/JCI112669","article-title":"Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s)","volume":"78","author":"Balavoine","year":"1986","journal-title":"J Clin Invest"},{"key":"B77","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/344633a0","article-title":"Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein","volume":"344","author":"Carter","year":"1990","journal-title":"Nature"},{"key":"B78","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/0167-5699(91)90142-G","article-title":"Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro","volume":"12","author":"Dinarello","year":"1991","journal-title":"Immunol Today"},{"key":"B79","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","article-title":"Affibody molecules in biotechnological and medical applications","volume":"35","author":"Stahl","year":"2017","journal-title":"Trends Biotechnol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/art.39995","article-title":"Anakinra for colchicine-resistant familial mediterranean fever: a randomized, double-blind, placebo-controlled trial","volume":"69","author":"Ben-Zvi","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/acr.23446","article-title":"Nationwide experience with off-label use of interleukin-1 targeting treatment in familial mediterranean fever patients","volume":"70","author":"Akar","year":"2018","journal-title":"Arthritis Care Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/ard.2010.143438","article-title":"Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis","volume":"70","author":"Obici","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/art.23475","article-title":"Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1136\/ard.2011.149922","article-title":"On-demand anakinra treatment is effective in mevalonate kinase deficiency","volume":"70","author":"Bodar","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B85","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jpeds.2010.02.040","article-title":"Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with anakinra","volume":"157","author":"Lepore","year":"2010","journal-title":"J Pediatr"},{"key":"B86","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJMoa055137","article-title":"Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition","volume":"355","author":"Goldbach-Mansky","year":"2006","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/art.30149","article-title":"Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome","volume":"63","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B88","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/art.20033","article-title":"Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra","volume":"50","author":"Hawkins","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B89","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2310\/7750.2008.07050","article-title":"Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up","volume":"12","author":"Ross","year":"2008","journal-title":"J Cutan Med Surg"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(04)17401-1","article-title":"Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist","volume":"364","author":"Hoffman","year":"2004","journal-title":"Lancet"},{"key":"B91","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.25057","article-title":"Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease\/chronic infantile neurologic, cutaneous, articular syndrome","volume":"62","author":"Neven","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/archderm.142.12.1591","article-title":"Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1\/NALP3 mutations","volume":"142","author":"Leslie","year":"2006","journal-title":"Arch Dermatol"},{"key":"B93","first-page":"593","article-title":"A case of resistant adult-onset periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome responsive to anakinra","volume":"30","author":"Cantarini","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"7148","DOI":"10.1073\/pnas.1103681108","article-title":"Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade","volume":"108","author":"Stojanov","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the treatment of autoinflammatory recurrent fever syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1002\/art.38777","article-title":"Canakinumab for the treatment of children with colchicine-resistant familial mediterranean fever: a 6-month open-label, single-arm pilot study","volume":"66","author":"Brik","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13075-015-0765-4","article-title":"Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial mediterranean fever","volume":"17","author":"Gul","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B98","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1136\/annrheumdis-2015-209031","article-title":"Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study","volume":"76","author":"Gattorno","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/art.40146","article-title":"Open-Label, phase ii study to assess the efficacy and safety of canakinumab treatment in active hyperimmunoglobulinemia d with periodic fever syndrome","volume":"69","author":"Arostegui","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1136\/ard.2011.152728","article-title":"Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes","volume":"70","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B101","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1186\/ar4184","article-title":"The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age","volume":"15","author":"Caorsi","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"R202","DOI":"10.1186\/ar3535","article-title":"Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study","volume":"13","author":"Kone-Paut","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B104","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/ar4237","article-title":"Treatment of muckle-wells syndrome: analysis of two IL-1-blocking regimens","volume":"15","author":"Kuemmerle-Deschner","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04389-3","article-title":"IL-1beta blockade in periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: case-based review","author":"Soylu","year":"2019","journal-title":"Rheumatol Int."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/1756-185X.12722","article-title":"Canakinumab efficacy in refractory adult-onset PFAPA syndrome","volume":"20","author":"Lopalco","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"B107","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7326\/0003-4819-157-8-201210160-00003","article-title":"Rilonacept for colchicine-resistant or -intolerant familial mediterranean fever: a randomized trial","volume":"157","author":"Hashkes","year":"2012","journal-title":"Ann Intern Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.clinthera.2012.09.009","article-title":"Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study","volume":"34","author":"Hoffman","year":"2012","journal-title":"Clin Ther"},{"key":"B110","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12016-013-8358-y","article-title":"IL-1beta biological treatment of familial Mediterranean fever","volume":"45","author":"Soriano","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/2050-6511-14-40","article-title":"Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes","volume":"14","author":"Urien","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/jps.2600840511","article-title":"Kidney as a major clearance organ for recombinant human interleukin-1 receptor antagonist","volume":"84","author":"Kim","year":"1995","journal-title":"J Pharm Sci"},{"key":"B113","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0009-9236(03)00094-8","article-title":"Pharmacokinetics of anakinra in subjects with different levels of renal function","volume":"74","author":"Yang","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.psyneuen.2007.09.004","article-title":"A dual role for interleukin-1 in hippocampal-dependent memory processes","volume":"32","author":"Goshen","year":"2007","journal-title":"Psychoneuroendocrinology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/RHU.0b013e31823682f5","article-title":"Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and\/or sacroiliitis who were resistant to colchicine treatment","volume":"17","author":"Bilgen","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3109\/s10165-011-0463-2","article-title":"Anti-TNF agents in familial mediterranean fever: report of three cases and review of the literature","volume":"21","author":"Ozgocmen","year":"2011","journal-title":"Mod Rheumatol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/acr.23120","article-title":"International retrospective chart review of treatment patterns in severe FMF, TRAPS and MKD\/HIDS","volume":"69","author":"Ozen","year":"2017","journal-title":"Arthritis Care Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/art.33416","article-title":"Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study","volume":"64","author":"Bulua","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/art.21965","article-title":"A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents","volume":"54","author":"Matsubara","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B120","first-page":"150","article-title":"Interleukin-6 targeting therapy in familial mediterranean fever","volume":"31","author":"Fujikawa","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3109\/14397595.2014.908810","article-title":"Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial mediterranean fever","volume":"26","author":"Hamanoue","year":"2016","journal-title":"Mod Rheumatol"},{"key":"B122","first-page":"S169","article-title":"Remission of nephrotic syndrome due to AA-amyloidosis, complicating familiar mediterranean fever, with tocilizumab","volume":"33","author":"Serelis","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1111\/1756-185X.12776","article-title":"Tocilizumab is effective in a familial mediterranean fever patient complicated with histologically proven recurrent fasciitis and myositis","volume":"20","author":"Umeda","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1093\/rheumatology\/kex180","article-title":"Successful use of tocilizumab in two cases of severe autoinflammatory disease with a single copy of the mediterranean fever gene","volume":"56","author":"Nikiphorou","year":"2017","journal-title":"Rheumatology"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2169\/internalmedicine.2277-18","article-title":"Atypical familial mediterranean fever complicated with gastrointestinal amyloidosis diagnosed due to paroxysmal arthralgia and intractable diarrhea, successfully treated with tocilizumab","volume":"58","author":"Aikawa","year":"2019","journal-title":"Intern Med"},{"key":"B126","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/rheumatology\/keu474","article-title":"Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial mediterranean fever","volume":"54","author":"Yilmaz","year":"2015","journal-title":"Rheumatology"},{"key":"B127","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13023-017-0642-0","article-title":"Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever","volume":"12","author":"Ugurlu","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"B128","doi-asserted-by":"publisher","first-page":"278","DOI":"10.5152\/eurjrheum.2018.17183","article-title":"Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF","volume":"5","author":"Yilmaz","year":"2018","journal-title":"Eur J Rheumatol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00296-015-3305-2","article-title":"Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS)","volume":"35","author":"La Torre","year":"2015","journal-title":"Rheumatol Int"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/art.30215","article-title":"Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab","volume":"63","author":"Vaitla","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B131","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5152\/eurjrheumatol.2014.14053","article-title":"Successful treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with tocilizumab: a case report","volume":"2","author":"Akasbi","year":"2015","journal-title":"Eur J Rheumatol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/01.RHU.0000442576.41537.de","article-title":"Interleukin 6 blockade for hyperimmunoglobulin D and periodic fever syndrome","volume":"20","author":"Shendi","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/rheumatology\/keu341","article-title":"TLR2\/TLR4-dependent exaggerated cytokine production in hyperimmunoglobulinaemia D and periodic fever syndrome","volume":"54","author":"Stoffels","year":"2015","journal-title":"Rheumatology"},{"key":"B134","first-page":"S46","article-title":"Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature","volume":"33","author":"Lane","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"bcr2015210513","DOI":"10.1136\/bcr-2015-210513","article-title":"Anti-interleukin 6 receptor therapy for hyper-IgD syndrome","volume":"2015","author":"Musters","year":"2015","journal-title":"BMJ Case Rep"},{"key":"B136","doi-asserted-by":"publisher","first-page":"3514645","DOI":"10.1155\/2018\/3514645","article-title":"Tocilizumab for the treatment of mevalonate kinase deficiency","volume":"2018","author":"Rafiq","year":"2018","journal-title":"Case Rep Pediatr"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/rheumatology\/ket121","article-title":"Failure of tocilizumab treatment in a CINCA patient: clinical and pathogenic implications","volume":"52","author":"Snegireva","year":"2013","journal-title":"Rheumatology"},{"key":"B138","first-page":"88","article-title":"Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial mediterranean fever","volume":"42","author":"Gok","year":"2017","journal-title":"Acta Reumatol Port"},{"key":"B139","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/rheumatology\/key384","article-title":"Tofacitinib for familial mediterranean fever: a new alternative therapy?","volume":"58","author":"Garcia-Robledo","year":"2019","journal-title":"Rheumatology"},{"key":"B140","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00296-019-04490-7","article-title":"Tofacitinib for the treatment for colchicine-resistant familial mediterranean fever: case-based review","volume":"40","author":"Karadeniz","year":"2019","journal-title":"Rheumatol Int."},{"key":"B141","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/rheumatology\/ker146","article-title":"The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the british society for rheumatology biologics register","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/intimm\/dxn071","article-title":"Contribution of IL-1 to resistance to Streptococcus pneumoniae infection","volume":"20","author":"Kafka","year":"2008","journal-title":"Int Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005121.pub3","article-title":"Anakinra for rheumatoid arthritis","author":"Mertens","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"B146","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"Gotestam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B147","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00393-017-0354-9","article-title":"[IL-1-blockade with anakinra during pregnancy : retrospective analysis of efficacy and safety in female patients with familial mediterranean fever]","volume":"77","author":"Venhoff","year":"2018","journal-title":"Z Rheumatol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1002\/art.38811","article-title":"Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS)","volume":"66","author":"Chang","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/art.40055","article-title":"Cerebrospinal fluid cytokines correlate with aseptic meningitis and blood-brain barrier function in neonatal-onset multisystem inflammatory disease: central nervous system biomarkers in neonatal-onset multisystem inflammatory disease correlate with central nervous system inflammation","volume":"69","author":"Rodriguez-Smith","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1136\/annrheumdis-2013-204877","article-title":"A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease","volume":"74","author":"Sibley","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B151","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","article-title":"Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1beta monoclonal antibody","volume":"51","author":"Chakraborty","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"B152","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/rheumatology\/kex305","article-title":"International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors","volume":"56","author":"Youngstein","year":"2017","journal-title":"Rheumatology"},{"key":"B153","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/annrheumdis-2016-eular.4865","article-title":"Efficacy and safety of canakinumab in patients with cryopyrin associated periodic syndromes: an open- label, phase-III, extension study","volume":"75","author":"Brogan","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B155","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jcph.372","article-title":"Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis","volume":"55","author":"Autmizguine","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1177\/0091270009351882","article-title":"Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD)","volume":"50","author":"Radin","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3899\/jrheum.131226","article-title":"Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study","volume":"41","author":"Sundy","year":"2014","journal-title":"J Rheumatol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/BTT.S102954","article-title":"Efficacy of anti-IL-1 treatment in familial mediterranean fever: a systematic review of the literature","volume":"10","author":"van der Hilst","year":"2016","journal-title":"Biologics"},{"key":"B160","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10067-018-4230-z","article-title":"On demand use of anakinra for attacks of familial mediterranean fever (FMF)","volume":"38","author":"Babaoglu","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10753-014-0004-1","article-title":"Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean fever","volume":"38","author":"Cetin","year":"2015","journal-title":"Inflammation"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00296-015-3293-2","article-title":"Treatment of colchicine-resistant familial mediterranean fever in children and adolescents","volume":"35","author":"Eroglu","year":"2015","journal-title":"Rheumatol Int"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1136\/ard.2010.146878","article-title":"The efficacy of canakinumab in the treatment of a patient with familial mediterranean fever and longstanding destructive arthritis","volume":"70","author":"Mitroulis","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B164","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1136\/annrheumdis-2017-eular.5655","article-title":"Improvement of disease activity in patients with colchicine-resistant FMF, HIDS\/MKD and TRAPS assessed by autoinflammatory disease activity index (AIDAI): results from the cluster trial","volume":"76","author":"Kone-Paut","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1093\/rheumatology\/kev111","article-title":"On-demand treatment with anakinra: a treatment option for selected TRAPS patients","volume":"54","author":"Grimwood","year":"2015","journal-title":"Rheumatology"},{"key":"B166","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/hmg\/ddq455","article-title":"Protein kinase a regulates caspase-1 via Ets-1 in bone stromal cell-derived lesions: a link between cyclic AMP and pro-inflammatory pathways in osteoblast progenitors","volume":"20","author":"Almeida","year":"2011","journal-title":"Hum Mol Genet"},{"key":"B167","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/art.38912","article-title":"Enhanced chondrogenesis of induced pluripotent stem cells from patients with neonatal-onset multisystem inflammatory disease occurs via the caspase 1-independent cAMP\/protein kinase A\/CREB pathway","volume":"67","author":"Yokoyama","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/jcbfm.2010.103","article-title":"Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study","volume":"31","author":"Galea","year":"2011","journal-title":"J Cereb Blood Flow Metab"},{"key":"B169","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/0194599811402296","article-title":"Cryopyrin-associated periodic syndromes: otolaryngologic and audiologic manifestations","volume":"145","author":"Ahmadi","year":"2011","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B170","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/rheumatology\/kew208","article-title":"Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes","volume":"55","author":"Kullenberg","year":"2016","journal-title":"Rheumatology"},{"key":"B171","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/978-1-4419-6612-4_43","article-title":"Lessons from anti-TNF biologics: infliximab failure in a TRAPS family with the T50M mutation in TNFRSF1A","volume":"691","author":"Nedjai","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jid.2016.02.015","article-title":"JAK1\/2 Inhibitor ruxolitinib controls a case of chilblain lupus erythematosus","volume":"136","author":"Wenzel","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/annrheumdis-2016-209841","article-title":"Familial chilblain lupus due to a gain-of-function mutation in STING","volume":"76","author":"Konig","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12115","article-title":"Therapies in aicardi-goutieres syndrome","volume":"175","author":"Crow","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.3389\/fimmu.2019.02538","article-title":"Pharmacological inhibitors of the NLRP3 inflammasome","volume":"10","author":"Zahid","year":"2019","journal-title":"Front Immunol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1186\/s13063-018-3105-6","article-title":"Comparison of the efficacy and safety of tocilizumab forcolchicine-resistant or colchicine-intolerant familial mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial","volume":"19","author":"Koga","year":"2018","journal-title":"Trials"},{"key":"B178","doi-asserted-by":"publisher","first-page":"e18328","DOI":"10.1097\/MD.0000000000018328","article-title":"An open-label continuation trial of tocilizumab for familial mediterranean fever with colchicine ineffective or intolerance: Study protocol for investigator-initiated, multicenter, open-label trial","volume":"99","author":"Koga","year":"2020","journal-title":"Medicine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00865\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T05:23:36Z","timestamp":1591161816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00865\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":178,"alternative-id":["10.3389\/fimmu.2020.00865"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00865","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"article-number":"865"}}